| Recruiting | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Car NCT07202247 | City of Hope Medical Center | Phase 2 |
| Recruiting | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial NCT06650579 | Emory University | Phase 3 |
| Active Not Recruiting | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer NCT05779943 | Emory University | Phase 2 |
| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side NCT05722288 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer NCT05034562 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Pro NCT04519879 | City of Hope Medical Center | Phase 2 |
| Recruiting | 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer NCT04857502 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer NCT03902951 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prosta NCT03698370 | Andrei Iagaru | Phase 2 |
| Active Not Recruiting | Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation NCT04457232 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer NCT04190446 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer NCT03796767 | University of Utah | Phase 2 |
| Completed | Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prosta NCT03515577 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy NCT03582774 | Jonsson Comprehensive Cancer Center | Phase 3 |
| Active Not Recruiting | Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE NCT03371719 | NRG Oncology | Phase 2 |
| Active Not Recruiting | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer NCT02881242 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment NCT02673151 | Andrei Iagaru | Phase 2 / Phase 3 |
| Active Not Recruiting | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer NCT03016741 | Northwestern University | Phase 4 |
| Completed | Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Ra NCT02899221 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Completed | Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer NCT03122743 | Wake Forest University Health Sciences | — |
| Unknown | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Can NCT02935205 | Mamta Parikh | Phase 1 / Phase 2 |
| Completed | Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate C NCT03123978 | Mamta Parikh | Phase 1 |
| Terminated | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies NCT02985021 | Seattle Institute for Biomedical and Clinical Research | Phase 2 |
| Active Not Recruiting | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer NCT02807805 | Mamta Parikh | Phase 2 |
| Completed | Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy NCT02940262 | Jonsson Comprehensive Cancer Center | Phase 3 |
| Completed | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant NCT02601014 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer NCT02532114 | University of Washington | Phase 1 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer NCT02522715 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer NCT02499835 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Terminated | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progr NCT02420652 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer NCT02488070 | Stanford University | Phase 1 / Phase 2 |
| Completed | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cance NCT02159950 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated Wit NCT02312557 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Ca NCT02206334 | NRG Oncology | Phase 1 |
| Completed | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide NCT02099864 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer NCT01787331 | University of California, San Francisco | Phase 2 |
| Completed | Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel- NCT01833208 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy NCT01953640 | Mayo Clinic | — |
| Completed | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant NCT02228265 | OHSU Knight Cancer Institute | — |
| Active Not Recruiting | Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurren NCT01786265 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01503229 | University of Washington | Phase 2 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-R NCT01576172 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Tivantinib in Treating Patients With Metastatic Prostate Cancer NCT01519414 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer NCT01251861 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly D NCT01120236 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistan NCT01145508 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After Firs NCT01253642 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer NCT01026623 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients Wit NCT00936975 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate o NCT01050504 | University of Washington | — |
| Completed | Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Re NCT00486642 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate NCT00536991 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With NCT00108732 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer NCT00170157 | Mayo Clinic | Phase 2 |
| Completed | Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer NCT00064129 | National Cancer Institute (NCI) | Phase 1 |
| No Longer Available | F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer NCT03501940 | Andrei Iagaru | — |